These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 29039022)

  • 1. Metformin Inhibits the Development of L-DOPA-Induced Dyskinesia in a Murine Model of Parkinson's Disease.
    Ryu YK; Park HY; Go J; Choi DH; Kim YH; Hwang JH; Noh JR; Lee TG; Lee CH; Kim KS
    Mol Neurobiol; 2018 Jul; 55(7):5715-5726. PubMed ID: 29039022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastrodia elata Blume alleviates L-DOPA-induced dyskinesia by normalizing FosB and ERK activation in a 6-OHDA-lesioned Parkinson's disease mouse model.
    Doo AR; Kim SN; Hahm DH; Yoo HH; Park JY; Lee H; Jeon S; Kim J; Park SU; Park HJ
    BMC Complement Altern Med; 2014 Mar; 14():107. PubMed ID: 24650244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antidyskinetic Effect of 7-Nitroindazole and Sodium Nitroprusside Associated with Amantadine in a Rat Model of Parkinson's Disease.
    Bortolanza M; Bariotto-Dos-Santos KD; Dos-Santos-Pereira M; da-Silva CA; Del-Bel E
    Neurotox Res; 2016 Jul; 30(1):88-100. PubMed ID: 27053252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gadd45β ameliorates L-DOPA-induced dyskinesia in a Parkinson's disease mouse model.
    Park HY; Ryu YK; Kim YH; Park TS; Go J; Hwang JH; Choi DH; Rhee M; Lee CH; Kim KS
    Neurobiol Dis; 2016 May; 89():169-79. PubMed ID: 26875664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
    Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease.
    Johnston TH; Versi E; Howson PA; Ravenscroft P; Fox SH; Hill MP; Reidenberg BE; Corey R; Brotchie JM
    Neuropharmacology; 2018 Mar; 131():116-127. PubMed ID: 29197517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic SKF83959 induced less severe dyskinesia and attenuated L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
    Zhang H; Ma L; Wang F; Chen J; Zhen X
    Neuropharmacology; 2007 Jul; 53(1):125-33. PubMed ID: 17553535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered adenosine 2A and dopamine D2 receptor availability in the 6-hydroxydopamine-treated rats with and without levodopa-induced dyskinesia.
    Zhou X; Doorduin J; Elsinga PH; Dierckx RAJO; de Vries EFJ; Casteels C
    Neuroimage; 2017 Aug; 157():209-218. PubMed ID: 28583881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.
    Tronci E; Lisci C; Stancampiano R; Fidalgo C; Collu M; Devoto P; Carta M
    Neurobiol Dis; 2013 Dec; 60():108-14. PubMed ID: 24004632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treadmill Exercise Attenuates L-DOPA-Induced Dyskinesia and Increases Striatal Levels of Glial Cell-Derived Neurotrophic Factor (GDNF) in Hemiparkinsonian Mice.
    Speck AE; Schamne MG; S Aguiar A; Cunha RA; Prediger RD
    Mol Neurobiol; 2019 Apr; 56(4):2944-2951. PubMed ID: 30073506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The multimodal serotonin compound Vilazodone alone, but not combined with the glutamate antagonist Amantadine, reduces l-DOPA-induced dyskinesia in hemiparkinsonian rats.
    Cohen SR; Terry ML; Coyle M; Wheelis E; Centner A; Smith S; Glinski J; Lipari N; Budrow C; Manfredsson FP; Bishop C
    Pharmacol Biochem Behav; 2022 Jun; 217():173393. PubMed ID: 35513119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
    Kobylecki C; Crossman AR; Ravenscroft P
    Exp Neurol; 2013 Sep; 247():476-84. PubMed ID: 23360800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acupuncture Alleviates Levodopa-Induced Dyskinesia via Melanin-Concentrating Hormone in Pitx3-Deficient aphakia and 6-Hydroxydopamine-Lesioned Mice.
    Kim YK; Lee AR; Park H; Yoo J; Ahn S; Jeon SH; Kim J; Park HJ
    Mol Neurobiol; 2019 Apr; 56(4):2408-2423. PubMed ID: 30030752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Kinase Fyn As a Novel Intermediate in L-DOPA-Induced Dyskinesia in Parkinson's Disease.
    Sanz-Blasco S; Bordone MP; Damianich A; Gomez G; Bernardi MA; Isaja L; Taravini IR; Hanger DP; Avale ME; Gershanik OS; Ferrario JE
    Mol Neurobiol; 2018 Jun; 55(6):5125-5136. PubMed ID: 28840468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease.
    Frau R; Savoia P; Fanni S; Fiorentini C; Fidalgo C; Tronci E; Stancampiano R; Meloni M; Cannas A; Marrosu F; Bortolato M; Devoto P; Missale C; Carta M
    Exp Neurol; 2017 May; 291():1-7. PubMed ID: 28131725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological antagonism of histamine H2R ameliorated L-DOPA-induced dyskinesia via normalization of GRK3 and by suppressing FosB and ERK in PD.
    Ahmed MR; Jayakumar M; Ahmed MS; Zamaleeva AI; Tao J; Li EH; Job JK; Pittenger C; Ohtsu H; Rajadas J
    Neurobiol Aging; 2019 Sep; 81():177-189. PubMed ID: 31306812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The roles of striatal serotonin and L -amino-acid decarboxylase on L-DOPA-induced Dyskinesia in a Hemiparkinsonian rat model.
    Gil S; Park C; Lee J; Koh H
    Cell Mol Neurobiol; 2010 Aug; 30(6):817-25. PubMed ID: 20232137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ondansetron, a highly selective 5-HT
    Kwan C; Frouni I; Bédard D; Hamadjida A; Huot P
    Eur J Pharmacol; 2020 Mar; 871():172914. PubMed ID: 31926127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serotonergic Regulation of Synaptic Dopamine Levels Mitigates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson's Disease.
    Chen YH; Kuo TT; Wang V; Cheng PW; Huang EY; Ma KH; Greig NH; Olson L; Hoffer BJ; Tseng KY
    J Parkinsons Dis; 2024; 14(5):941-964. PubMed ID: 38905058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin-converting enzyme inhibition prevents l-dopa-induced dyskinesia in a 6-ohda-induced mouse model of Parkinson's disease.
    Park HY; Lee GS; Go J; Ryu YK; Lee CH; Moon JH; Kim KS
    Eur J Pharmacol; 2024 Jun; 973():176573. PubMed ID: 38642669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.